Braving the sweltering heat of 35 degrees Celsius and battling the relentless heat waves, on the afternoon of July 23, a delegation of more than 10 members—including Mu Kezhen, Deputy Director of the Provincial Department of Industry and Information Technology; Ma Guang, Director of the Consumer Goods Division of the same department; and Zhang Yinghong, Director of the Pharmaceutical Division—visited our company to inspect and assess our production operations. Executive Vice President Wu Shaohui provided the visiting team with a detailed overview of our company’s development journey and current operational status, patiently answering their questions along the way. The delegation expressed admiration for our company’s steadfast commitment to advancing human health over the past decade, particularly in the fields of biochemical pharmaceuticals, with a strong focus on research, development, manufacturing, and sales of drugs targeting cardiovascular and cerebrovascular diseases, digestive disorders, cancer treatments, and neuropsychiatric conditions. Deputy Director Mu Kezhen emphasized the need to overcome the adverse effects of the pandemic, maintain unwavering confidence in growth, and accurately monitor emerging trends and developments within the industry. He urged companies to continuously strengthen technological upgrades and innovation efforts, thereby enhancing their core competitiveness. Meanwhile, all departments under the Provincial Department of Industry and Information Technology pledged to bolster their service mindset, proactively offering support by stepping up assistance in areas such as policies, technology, financing, and talent acquisition. These measures aim to create an optimal environment for enterprise growth, accelerate the implementation of supportive policies, and ensure the healthy and rapid development of businesses.

On August 12, during the height of summer, the Provincial Drug Administration held a symposium at our company to support the development of enterprises specializing in "two products and one medical device." Attendees included Wang Hong and Lan Wengchi, Deputy Directors of the Provincial Drug Administration; relevant officials from the Provincial Drug Administration's Departments of Pharmaceutical Distribution, Medical Device Management, and Production Supervision; Vice Mayor Xu Hui; and over 40 representatives from 15 pharmaceutical manufacturers, 3 medical device producers, and two pharmaceutical wholesale-retail chain headquarters based in our city. General Manager Xie Wenbo took the lead in briefing the attending leaders on our company's development progress. He then raised five key issues—namely, the market launch and sales of active pharmaceutical ingredients, batch changes in production lines, filing procedures, reporting protocols, and the renewal of the "Production License"—seeking guidance from the officials present. After carefully listening to reports from multiple pharmaceutical and medical device companies, the provincial drug administration officials provided detailed policy clarifications right on the spot. Vice Mayor Xu Hui delivered a speech, expressing gratitude to the provincial drug administration officials for braving the sweltering heat to conduct on-site consultations and address enterprises' concerns, particularly highlighting their extensive efforts during the COVID-19 pandemic. He emphasized that, under the guidance of the provincial bureau, the Liaoyuan Branch should actively contribute to the healthy growth of Liaoyuan's pharmaceutical industry. Additionally, he urged all pharmaceutical and medical device companies to promptly review and thoroughly implement the requirements, solutions, and measures proposed by the research team, always prioritizing the safety and quality of medicines above all else. By doing so, they can continuously enhance product quality and safety standards, ensuring that the public has access to reliable, high-quality medications.

On August 20, a development seminar of the Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance was held at Bodaweiye Pharmaceutical Co., Ltd., hosted by the Jilin Province Modern Traditional Chinese Medicine and Biopharmaceutical Base Construction Office and organized by Bodaweiye Pharmaceutical Co., Ltd. The event aimed to deepen the alliance's initiatives, foster the healthy growth of Jilin's chemical pharmaceutical industry, and drive technological innovation within the sector. Attending the meeting were representatives from the Jilin Provincial Department of Science and Technology, the Liaoyuan Municipal Bureau of Science and Technology, and the Management Committee of Liaoyuan Economic Development Zone. Additionally present were key leaders from Bodaweiye Pharmaceutical Co., Ltd., the chairman of the alliance’s board of directors, Duan Chengjun; the company’s general manager, Xie Wenbo; as well as executives from other alliance member companies, including Xue Chuanxiao, Chairman of Shihuida Pharmaceutical Group Co., Ltd., and Zhang Jun, Chairman of Xidian Pharmaceutical Technology Development Co., Ltd. Also in attendance were nearly 30 participants, including Li Hao, Dean of the School of Pharmacy at Yanbian University, along with representatives from four leading universities and research institutions. During the seminar, Duan Chengjun, Chairman of Bodaweiye Pharmaceutical Co., Ltd., and other pharmaceutical company leaders delivered keynote speeches. Attendees then engaged in discussions centered on the alliance’s operational mechanisms, management models, and priority tasks. Topics included technical needs and collaborative projects among members related to chemical drug R&D, pilot-scale testing, and production, as well as strategies for joint applications by alliance members to the 2016 Jilin Provincial Science and Technology Development Plan projects. Participants also shared ideas aimed at further clarifying the alliance’s strengths, strengthening collaboration, and leveraging complementary advantages, ultimately outlining specific goals and responsibilities for the alliance’s future activities. The meeting concluded with the adoption of a rotating chairmanship system, designating Xue Chuanxiao, Chairman of Shihuida Pharmaceutical Group Co., Ltd., as the 2016 rotating chairperson. Additionally, a specialized Technical Expert Committee was established, with Su Li, Director of the Jilin Provincial Institute of Pharmaceutical Research, appointed as its chairperson. Finally, a permanent secretariat was set up, and Liu Daocheng, Secretary-General of the Jilin Provincial Pharmaceutical Industry Association, was appointed as the alliance’s executive secretary-general. This meeting marked a significant step forward in fully advancing the work of the Jilin Province Chemical Pharmaceutical Industry Technology Innovation Strategic Alliance, ensuring that its operations move toward greater scientific rigor, regularity, and institutionalization. It also enhanced the proactive engagement and enthusiasm of alliance members, fostering a mutually beneficial, interconnected, and highly efficient operating framework. Ultimately, these developments signify that the Jilin Province Chemical Pharmaceutical Innovation Strategic Alliance has entered a new phase of growth and maturity.

On March 9, to carry forward the traditional virtues of respecting and caring for the elderly, Xie Wenbo, member of the Liaoyuan Municipal Committee of the China Association for Promoting Democracy (CAPD), Director of the CAPD Liaoyuan Development Zone Branch, and General Manager of Jilin Boda Weiye Pharmaceutical Co., Ltd., led branch committee members and all CAPD Youth League members from Boda Weiye Pharmaceutical to visit and extend warm greetings to the elderly residents at Liaoyuan Social Welfare Institute, bringing along heartfelt blessings. Jiang Pengjun, Deputy Director of the Liaoyuan Municipal Committee of CAPD, and Jiang Liansheng, Secretary-General, also joined the慰问活动. At 2 p.m., led by Xie Wenbo, CAPD Development Zone Branch committee members and Boda Weiye Pharmaceutical’s Youth League members delivered a variety of daily necessities—worth a total of 5,000 yuan—including rice, 250 kilograms of flour, apples, tangyuan (sweet rice balls), cooking oil, as well as medicine valued at 3,000 yuan—to the social welfare institute. In addition, the CAPD Development Zone Branch brought along medical staff to conduct health check-ups for the elderly. They also invited a professional performing arts group from Liaoyuan City to entertain the residents with comedic dialogues, skits, and errenzhuan performances. Located in Liming Village, Longshan District, Liaoyuan City, the Liaoyuan Social Welfare Institute is home to more than 150 elderly individuals year-round. The arrival of the CAPD delegation quietly transformed the daily lives of these residents. “As mountains often harbor ancient pines that stand for millennia, it’s rare indeed for humans to reach the age of one hundred.” During their conversation, upon learning that the oldest resident at the institute was 90 years old, the CAPD Development Zone Branch members warmly chatted with the seniors, personally handing them each piece of fruit. As the elderly gratefully accepted the fruits, their faces lit up with joy, beaming ear-to-ear and repeatedly saying, “Thank you!” Throughout the visit, Xie Wenbo attentively inquired about the seniors’ current family situations, living conditions, and health status, gently reminding them to stay warm, guard against illnesses, and prioritize safety. His thoughtful care made the elderly feel as though their own beloved son had returned home—warm, comforting, and deeply moving.

Grand Celebration of Broad Achievements

National Launch Event for Class III New Drug, Polypruzine Zinc

From July 6 to 7, 2013, a symposium was grandly held at the China World Hotel in Beijing to discuss the protocol for the "Multicenter, Randomized, Parallel-Controlled Clinical Study on Triple Therapy Combined with Polyprazin (3+P Therapy) for Helicobacter pylori-Associated Gastritis." The study was sponsored by Jilin Boda Weiye Pharmaceutical Co., Ltd., with Peking Union Medical College Hospital serving as the leading institution. Participating centers included Shanghai Renji Hospital, Jiangsu Provincial People's Hospital, Xiamen Zhongshan Hospital, the First Hospital of Jilin University, the First Affiliated Hospital of Nanchang University, Shandong Qilu Hospital, Xiangya Hospital, and the First Affiliated Hospital of Zhejiang University School of Medicine. A total of 17 experts from 11 participating centers attended the meeting to review and refine the preliminary draft of the trial protocol. Discussions focused on enhancing the trial design, improving the informed consent form, clarifying inclusion and exclusion criteria, defining key assessment metrics, and ensuring that all stakeholders—experts and investigators alike—are fully informed about the entire study process. This collaborative effort aims to make the "Triple Therapy Combined with Polyprazin (3+P Therapy) for Helicobacter pylori-Associated Gastritis" clinical study more rigorous, scientifically sound, and ethically compliant.